HHM Wealth Advisors LLC lessened its holdings in shares of MetLife, Inc. (NYSE:MET – Get Rating) by 27.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 928 shares of the financial services provider’s stock after selling 355 shares during the period. HHM Wealth Advisors LLC’s holdings in MetLife were worth $56,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of MetLife by 92.5% during the third quarter. Barclays PLC now owns 5,264,670 shares of the financial services provider’s stock valued at $319,989,000 after acquiring an additional 2,530,149 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in MetLife by 3,664.1% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 1,959,014 shares of the financial services provider’s stock worth $123,007,000 after purchasing an additional 1,906,969 shares during the last quarter. Truist Financial Corp grew its position in MetLife by 296.5% in the 3rd quarter. Truist Financial Corp now owns 1,497,828 shares of the financial services provider’s stock worth $91,038,000 after purchasing an additional 1,120,079 shares during the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of MetLife in the third quarter valued at approximately $63,934,000. Finally, Ensign Peak Advisors Inc boosted its position in shares of MetLife by 309.7% during the first quarter. Ensign Peak Advisors Inc now owns 1,364,265 shares of the financial services provider’s stock worth $95,881,000 after buying an additional 1,031,277 shares during the period. Institutional investors and hedge funds own 88.15% of the company’s stock.
MetLife Trading Up 0.4 %
Shares of MET opened at $70.97 on Wednesday. The business’s 50-day moving average price is $73.23 and its 200 day moving average price is $68.44. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $55.68 billion, a P/E ratio of 26.68, a P/E/G ratio of 2.14 and a beta of 1.07. MetLife, Inc. has a 1-year low of $57.41 and a 1-year high of $77.36.
MetLife Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 7th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, February 6th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.82%. MetLife’s payout ratio is currently 75.19%.
Insider Transactions at MetLife
In related news, EVP Bill Pappas sold 5,000 shares of the company’s stock in a transaction on Wednesday, December 7th. The stock was sold at an average price of $75.55, for a total transaction of $377,750.00. Following the transaction, the executive vice president now directly owns 65,147 shares of the company’s stock, valued at $4,921,855.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Steven J. Goulart sold 29,401 shares of the firm’s stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $71.88, for a total transaction of $2,113,343.88. Following the completion of the sale, the executive vice president now directly owns 273,310 shares in the company, valued at $19,645,522.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Bill Pappas sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 7th. The shares were sold at an average price of $75.55, for a total transaction of $377,750.00. Following the completion of the transaction, the executive vice president now owns 65,147 shares in the company, valued at approximately $4,921,855.85. The disclosure for this sale can be found here. Insiders sold a total of 37,401 shares of company stock valued at $2,706,824 over the last quarter. Company insiders own 0.26% of the company’s stock.
Wall Street Analyst Weigh In
MET has been the topic of several analyst reports. Citigroup raised their target price on MetLife from $77.00 to $84.00 in a research report on Wednesday, November 16th. Morgan Stanley lifted their price objective on shares of MetLife from $87.00 to $88.00 and gave the company an “overweight” rating in a research note on Tuesday, January 10th. StockNews.com assumed coverage on shares of MetLife in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Wells Fargo & Company boosted their price target on shares of MetLife from $81.00 to $83.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 18th. Finally, JPMorgan Chase & Co. increased their price objective on shares of MetLife from $77.00 to $80.00 and gave the company an “overweight” rating in a report on Friday, January 6th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.18.
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
- Get a free copy of the StockNews.com research report on MetLife (MET)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.